Global Giant Cell Arteritis Therapeutic market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Giant Cell Arteritis Therapeutic Market Growth (Status and Outlook) 2025-2031

The global Giant Cell Arteritis Therapeutic market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age. United States market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. China market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Europe market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031. Global key Giant Cell Arteritis Therapeutic players cover Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024. LPI (LP Information) newest research report, the Giant Cell Arteritis Therapeutic Industry Forecast looks at past sales and reviews total world Giant Cell Arteritis Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Giant Cell Arteritis Therapeutic sales for 2025 through 2031. With Giant Cell Arteritis Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Giant Cell Arteritis Therapeutic industry. This Insight Report provides a comprehensive analysis of the global Giant Cell Arteritis Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Giant Cell Arteritis Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Giant Cell Arteritis Therapeutic market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Giant Cell Arteritis Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Giant Cell Arteritis Therapeutic. This report presents a comprehensive overview, market shares, and growth opportunities of Giant Cell Arteritis Therapeutic market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Prednisone &nbsp;&nbsp;&nbsp; Methotrexate &nbsp;&nbsp;&nbsp; Tocilizumab &nbsp;&nbsp;&nbsp; Aspirin Segmentation by Application: &nbsp;&nbsp;&nbsp; Corticosteroids &nbsp;&nbsp;&nbsp; Immunosuppressive Agents &nbsp;&nbsp;&nbsp; Anticoagulants &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Kiniksa Pharmaceuticals, Ltd. &nbsp;&nbsp;&nbsp; Regeneron &nbsp;&nbsp;&nbsp; GlaxoSmithKline plc &nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd. &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; AbbVie, Inc. &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company &nbsp;&nbsp;&nbsp; Abbott &nbsp;&nbsp;&nbsp; Johnson & Johnson Services, Inc. &nbsp;&nbsp;&nbsp; Johns Hopkins Hospital &nbsp;&nbsp;&nbsp; Fortis Healthcare &nbsp;&nbsp;&nbsp; American College of Rheumatology &nbsp;&nbsp;&nbsp; Duke University Health System &nbsp;&nbsp;&nbsp; Lahey Clinic Foundation

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Giant Cell Arteritis Therapeutic Market Size (2020-2031) &nbsp;2.1.2 Giant Cell Arteritis Therapeutic Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Giant Cell Arteritis Therapeutic by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Giant Cell Arteritis Therapeutic Segment by Type &nbsp;2.2.1 Prednisone &nbsp;2.2.2 Methotrexate &nbsp;2.2.3 Tocilizumab &nbsp;2.2.4 Aspirin &nbsp;2.3 Giant Cell Arteritis Therapeutic Market Size by Type &nbsp;2.3.1 Giant Cell Arteritis Therapeutic Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Giant Cell Arteritis Therapeutic Market Size Market Share by Type (2020-2025) &nbsp;2.4 Giant Cell Arteritis Therapeutic Segment by Application &nbsp;2.4.1 Corticosteroids &nbsp;2.4.2 Immunosuppressive Agents &nbsp;2.4.3 Anticoagulants &nbsp;2.4.4 Others &nbsp;2.5 Giant Cell Arteritis Therapeutic Market Size by Application &nbsp;2.5.1 Giant Cell Arteritis Therapeutic Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Giant Cell Arteritis Therapeutic Market Size Market Share by Application (2020-2025) 3 Giant Cell Arteritis Therapeutic Market Size by Player &nbsp;3.1 Giant Cell Arteritis Therapeutic Market Size Market Share by Player &nbsp;3.1.1 Global Giant Cell Arteritis Therapeutic Revenue by Player (2020-2025) &nbsp;3.1.2 Global Giant Cell Arteritis Therapeutic Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Giant Cell Arteritis Therapeutic Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Giant Cell Arteritis Therapeutic by Region &nbsp;4.1 Giant Cell Arteritis Therapeutic Market Size by Region (2020-2025) &nbsp;4.2 Global Giant Cell Arteritis Therapeutic Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Giant Cell Arteritis Therapeutic Market Size Growth (2020-2025) &nbsp;4.4 APAC Giant Cell Arteritis Therapeutic Market Size Growth (2020-2025) &nbsp;4.5 Europe Giant Cell Arteritis Therapeutic Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Giant Cell Arteritis Therapeutic Market Size by Country (2020-2025) &nbsp;5.2 Americas Giant Cell Arteritis Therapeutic Market Size by Type (2020-2025) &nbsp;5.3 Americas Giant Cell Arteritis Therapeutic Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Giant Cell Arteritis Therapeutic Market Size by Region (2020-2025) &nbsp;6.2 APAC Giant Cell Arteritis Therapeutic Market Size by Type (2020-2025) &nbsp;6.3 APAC Giant Cell Arteritis Therapeutic Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Giant Cell Arteritis Therapeutic Market Size by Country (2020-2025) &nbsp;7.2 Europe Giant Cell Arteritis Therapeutic Market Size by Type (2020-2025) &nbsp;7.3 Europe Giant Cell Arteritis Therapeutic Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Giant Cell Arteritis Therapeutic by Region (2020-2025) &nbsp;8.2 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Giant Cell Arteritis Therapeutic Market Forecast &nbsp;10.1 Global Giant Cell Arteritis Therapeutic Forecast by Region (2026-2031) &nbsp;10.1.1 Global Giant Cell Arteritis Therapeutic Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Giant Cell Arteritis Therapeutic Forecast &nbsp;10.1.3 APAC Giant Cell Arteritis Therapeutic Forecast &nbsp;10.1.4 Europe Giant Cell Arteritis Therapeutic Forecast &nbsp;10.1.5 Middle East & Africa Giant Cell Arteritis Therapeutic Forecast &nbsp;10.2 Americas Giant Cell Arteritis Therapeutic Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.2.2 Canada Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.2.3 Mexico Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.2.4 Brazil Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.3 APAC Giant Cell Arteritis Therapeutic Forecast by Region (2026-2031) &nbsp;10.3.1 China Giant Cell Arteritis Therapeutic Market Forecast &nbsp;10.3.2 Japan Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.3.3 Korea Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.3.4 Southeast Asia Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.3.5 India Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.3.6 Australia Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.4 Europe Giant Cell Arteritis Therapeutic Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.4.2 France Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.4.3 UK Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.4.4 Italy Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.4.5 Russia Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.5 Middle East & Africa Giant Cell Arteritis Therapeutic Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.5.2 South Africa Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.5.3 Israel Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.5.4 Turkey Market Giant Cell Arteritis Therapeutic Forecast &nbsp;10.6 Global Giant Cell Arteritis Therapeutic Forecast by Type (2026-2031) &nbsp;10.7 Global Giant Cell Arteritis Therapeutic Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Giant Cell Arteritis Therapeutic Forecast 11 Key Players Analysis &nbsp;11.1 Sanofi &nbsp;11.1.1 Sanofi Company Information &nbsp;11.1.2 Sanofi Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.1.3 Sanofi Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Sanofi Main Business Overview &nbsp;11.1.5 Sanofi Latest Developments &nbsp;11.2 Kiniksa Pharmaceuticals, Ltd. &nbsp;11.2.1 Kiniksa Pharmaceuticals, Ltd. Company Information &nbsp;11.2.2 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Kiniksa Pharmaceuticals, Ltd. Main Business Overview &nbsp;11.2.5 Kiniksa Pharmaceuticals, Ltd. Latest Developments &nbsp;11.3 Regeneron &nbsp;11.3.1 Regeneron Company Information &nbsp;11.3.2 Regeneron Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.3.3 Regeneron Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Regeneron Main Business Overview &nbsp;11.3.5 Regeneron Latest Developments &nbsp;11.4 GlaxoSmithKline plc &nbsp;11.4.1 GlaxoSmithKline plc Company Information &nbsp;11.4.2 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 GlaxoSmithKline plc Main Business Overview &nbsp;11.4.5 GlaxoSmithKline plc Latest Developments &nbsp;11.5 F. Hoffmann-La Roche Ltd. &nbsp;11.5.1 F. Hoffmann-La Roche Ltd. Company Information &nbsp;11.5.2 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 F. Hoffmann-La Roche Ltd. Main Business Overview &nbsp;11.5.5 F. Hoffmann-La Roche Ltd. Latest Developments &nbsp;11.6 Novartis AG &nbsp;11.6.1 Novartis AG Company Information &nbsp;11.6.2 Novartis AG Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.6.3 Novartis AG Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Novartis AG Main Business Overview &nbsp;11.6.5 Novartis AG Latest Developments &nbsp;11.7 AbbVie, Inc. &nbsp;11.7.1 AbbVie, Inc. Company Information &nbsp;11.7.2 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 AbbVie, Inc. Main Business Overview &nbsp;11.7.5 AbbVie, Inc. Latest Developments &nbsp;11.8 Bristol-Myers Squibb Company &nbsp;11.8.1 Bristol-Myers Squibb Company Company Information &nbsp;11.8.2 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Bristol-Myers Squibb Company Main Business Overview &nbsp;11.8.5 Bristol-Myers Squibb Company Latest Developments &nbsp;11.9 Abbott &nbsp;11.9.1 Abbott Company Information &nbsp;11.9.2 Abbott Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.9.3 Abbott Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Abbott Main Business Overview &nbsp;11.9.5 Abbott Latest Developments &nbsp;11.10 Johnson & Johnson Services, Inc. &nbsp;11.10.1 Johnson & Johnson Services, Inc. Company Information &nbsp;11.10.2 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Johnson & Johnson Services, Inc. Main Business Overview &nbsp;11.10.5 Johnson & Johnson Services, Inc. Latest Developments &nbsp;11.11 Johns Hopkins Hospital &nbsp;11.11.1 Johns Hopkins Hospital Company Information &nbsp;11.11.2 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Johns Hopkins Hospital Main Business Overview &nbsp;11.11.5 Johns Hopkins Hospital Latest Developments &nbsp;11.12 Fortis Healthcare &nbsp;11.12.1 Fortis Healthcare Company Information &nbsp;11.12.2 Fortis Healthcare Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Fortis Healthcare Main Business Overview &nbsp;11.12.5 Fortis Healthcare Latest Developments &nbsp;11.13 American College of Rheumatology &nbsp;11.13.1 American College of Rheumatology Company Information &nbsp;11.13.2 American College of Rheumatology Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 American College of Rheumatology Main Business Overview &nbsp;11.13.5 American College of Rheumatology Latest Developments &nbsp;11.14 Duke University Health System &nbsp;11.14.1 Duke University Health System Company Information &nbsp;11.14.2 Duke University Health System Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Duke University Health System Main Business Overview &nbsp;11.14.5 Duke University Health System Latest Developments &nbsp;11.15 Lahey Clinic Foundation &nbsp;11.15.1 Lahey Clinic Foundation Company Information &nbsp;11.15.2 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product Offered &nbsp;11.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.15.4 Lahey Clinic Foundation Main Business Overview &nbsp;11.15.5 Lahey Clinic Foundation Latest Developments 12 Research Findings and Conclusion

Buyer Information

Order Summary

Report	Global Giant Cell Arteritis Therapeutic Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI39255